Skip to main content

Amanda Mei

(she/her/hers)

Associate

[email protected]

+1.617.210.6875

Share:

Amanda focuses her practice on securities transactions, public offerings, and other general corporate matters. She represents clients in different industries, primarily life sciences. Amanda has experience with representing clients in a variety of capital markets transactions, including initial public offerings, reverse mergers, follow-on offerings, and at-the-market offerings.

During law school, Amanda served as a legal extern with the Victim Rights Law Center in Boston where she helped sexual assault survivors with their legal needs, including U visa applications and asylum applications. She was also a member of the International Law Journal. Amanda served as treasurer of the Latin American Law Students Association and was a member of the Asian Pacific American Law Students Association.

Prior to attending law school, Amanda worked as a paralegal officer with a Boston-based investment bank, with a focus on regulatory filings and board governance for investment management companies. 

viewpoints

The OASB Annual Report to Congress for Fiscal Year 2020

March 15, 2021 | Blog | By Amanda Mei

In January 2019, the Office of the Advocate for Small Business Capital Formation (the “Office”) was formed “to advance the interests of small businesses and their investors at the SEC and in the capital markets.” These small businesses include early-stage start-ups, small public companies, and everything in between. Each year, the Office prepares an annual report to Congress, which among other things, explains issues that small businesses face with respect to raising capital, including a focus on minority- and women-owned businesses. Included are some of the highlights from this year’s annual report, including a few of the Office’s recommendations to Congress.
Read more

SEC Amends MD&A and Other Financial Disclosure Rules

February 5, 2021 | Alert | By Daniel T. Kajunski, Amanda Mei

This advisory summarizes SEC amendments, effective February 10, 202, to MD&A and other financial disclosure requirements and provides a chart highlighting the amended rules.
Read more

SEC Guidance on Key Performance Indicators and Metrics in MD&A and Three New MD&A C&DIs

February 26, 2020 | Advisory | By Daniel T. Kajunski, Amanda Mei

This advisory covers guidance from the SEC on the disclosure of key MD&A performance metrics and three new CD&Is.
Read more
Read less

News & Press

Press Release Thumbnail
Mintz advised Cardurion Pharmaceuticals, Inc., a biotechnology company developing novel therapeutics to treat heart failure and other cardiovascular diseases, in a private investment of up to $300 million from Bain Capital Life Sciences and Bain Capital Private Equity that will enable the Boston-based company to expand its drug discovery programs.
Press Release Thumbnail
Firm plays a key role in the largest health care acquisition to date in 2020.
Read less

Recognition & Awards

  • Richard Mintz Summer Associate Diversity Scholar (2017)
Read less

Amanda Mei

(she/her/hers)

Associate

Boston